Q2 2026 Cushing Syndrome and Hypercortisolism Market Advances in Treatment and Clinical Research

Isturisa highlighted growing U.S. adoption and opportunities in Cushing syndrome.

Korlym shared new clinical findings and raised awareness of hypercortisolism in high-risk patients.

Lifyorli advanced toward potential approval following the resubmission of relacorilant’s New Drug Application.